| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Inactive ASO (in vivo) sodium does not target any specific gene or protein in the rodent genome. It is intentionally designed with a scrambled or non-targeting sequence to lack complementarity to any known mRNA transcript. As a negative control, its purpose is to have no intended pharmacological activity, thereby mimicking the non-specific effects of active ASOs without producing target-specific knockdown.
|
|---|---|
| ln Vitro |
In cell-free assays, Inactive ASO sodium demonstrates no measurable binding to any known mRNA or protein targets, as confirmed by RNA pulldown or electrophoretic mobility shift assays. It does not activate RNase H or interfere with splicing, translation, or other RNA-processing mechanisms, making it a true negative control for ASO-based experiments.
|
| ln Vivo |
In cell culture experiments, Inactive ASO sodium does not alter target gene expression levels compared to untreated controls. It does not induce off-target effects such as cytokine release, cell death, or proliferation changes in various cell lines at concentrations up to 10 microM. The compound is commonly used as a control in transfection experiments alongside active therapeutic ASOs.
|
| Enzyme Assay |
To confirm inactivity in cell-free binding assays, the Inactive ASO sodium is incubated with lysates from relevant cell types or tissues. RNA pulldown experiments using biotin-labeled Inactive ASO are performed, followed by mass spectrometry or sequencing to identify any bound proteins or transcripts. No specific binding partners are identified, confirming the lack of target engagement.
|
| Cell Assay |
Cells are seeded in 6- or 12-well plates and transfected with Inactive ASO sodium using standard lipofection or electroporation methods (50-200 nM). After 24-72 hours, RNA and protein are extracted. Target gene expression is assessed by qRT-PCR and Western blot. No significant change in any measured transcript or protein is detected relative to mock-transfected controls.
|
| Animal Protocol |
In vivo studies use rodent models (typically mice or rats). Inactive ASO sodium is administered via intravenous, subcutaneous, or intrathecal injection at doses matching those used for the active therapeutic ASO (e.g., 10-50 mg/kg). Tissues are harvested at various time points (e.g., 1-28 days post-dose), and RNA and protein are extracted for gene expression analysis, confirming no unintended knockdown of any target.
|
| ADME/Pharmacokinetics |
Inactive ASO sodium exhibits pharmacokinetic properties characteristic of ASOs. Following systemic administration, it distributes widely to tissues, with the highest accumulation in the liver, kidney, and spleen. The compound is taken up by cells via endocytosis and remains predominantly in endosomal compartments. The half-life in tissues ranges from several days to weeks, depending on the chemical modifications present (e.g., phosphorothioate backbone, MOE modifications).
|
| Toxicity/Toxicokinetics |
Inactive ASO sodium is designed to have minimal toxicity in vivo. However, ASOs can cause dose-dependent adverse effects including elevated liver enzymes, complement activation, and pro-inflammatory cytokine release at high doses. This inactive control serves as a comparator to distinguish sequence-specific target engagement from class-related toxicities. No target-related toxicity is expected. The compound is well-tolerated at standard control doses.
|
| References | |
| Additional Infomation |
Inactive ASO (in vivo) sodium is intended for research use only and is not approved for clinical applications. It features phosphorothioate backbone modifications and 2‘-O-methoxyethyl (MOE) modifications for enhanced stability and reduced immunogenicity. All cytosines are 5'-methylcytosine to minimize potential immune recognition. The compound is commonly used as the negative control for Tofersen and other therapeutic ASOs.
|
| Appearance |
Solid powder
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
